Your browser doesn't support javascript.
Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022.
Robilotti, Elizabeth V; Whiting, Karissa; Lucca, Anabella; Poon, Chester; Jani, Krupa; McMillen, Tracy; Freeswick, Scott; Korenstein, Deborah; Babady, N Esther; Seshan, Venkatraman E; Kamboj, Mini.
  • Robilotti EV; Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Infection Control, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York
  • Whiting K; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lucca A; Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA; Employee Health Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Poon C; Division of Digital Informatics and Technology Solutions, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Jani K; Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • McMillen T; Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Freeswick S; Division of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Korenstein D; Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Babady NE; Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA; Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering
  • Seshan VE; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kamboj M; Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Infection Control, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York
Clin Microbiol Infect ; 28(12): 1624-1628, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2035886
ABSTRACT

OBJECTIVE:

To describe effectiveness of mRNA vaccines by comparing 2-dose (2D) and 3-dose (3D) healthcare worker (HCW) recipients in the setting of Omicron variant dominance. Performance of 2D and 3D vaccine series against SARS-CoV-2 variants and the clinical outcomes of HCWs may inform return-to-work guidance.

METHODS:

In a retrospective study from December 15, 2020 to January 15, 2022, SARS-CoV-2 infections among HCWs at a large tertiary cancer centre in New York City were examined to estimate infection rates (aggregated positive tests / person-days) and 95% CIs over the Omicron period in 3D and 2D mRNA vaccinated HCWs and were compared using rate ratios. We described the clinical features of post-vaccine infections and impact of prior (pre-Omicron) COVID infection on vaccine effectiveness.

RESULTS:

Among the 20857 HCWs in our cohort, 20,660 completed the 2D series with an mRNA vaccine during our study period and 12461 had received a third dose by January 15, 2022. The infection rate ratio for 3D versus 2D vaccinated HCWs was 0.667 (95% CI 0.623, 0.713) for an estimated 3D vaccine effectiveness of 33.3% compared to two doses only during the Omicron dominant period from December 15, 2021 to January 15, 2022. Breakthrough Omicron infections after 3D + 14 days occurred in 1,315 HCWs. Omicron infections were mild, with 16% of 3D and 11% 2D HCWs being asymptomatic.

DISCUSSION:

Study demonstrates improved vaccine-derived protection against COVID-19 infection in 3D versus 2D mRNA vaccinees during the Omicron surge. The advantage of 3D vaccination was maintained irrespective of prior COVID-19 infection status.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: North America Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: North America Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article